Or patent application, or shared rights agreement negotiation between KP and amarin

If we're speculating ... How about results so unexpectedly positive they've decided an independent confirmation of the data analysis is mandatory.

so EDDING gets to market the Reduce-IT indication in china without further negotiations with amarin? the original agreement preceded the successful results of the reduce-it trial.

https://investor.amarincorp.com/news-releases/news-release-details/amarin-and-eddingpharm-announce-agreement-develop-and

Late this year (are they hoping for something to occur at end of February?)

2022
Amarin to Report Fourth Quarter and Full Year 2021 Financial Results And Host Conference Call on March 1, 2022

2021
Amarin to Report Fourth Quarter and Full Year 2020 Results and Host Conference Call on February 25, 2021

2020
Amarin To Report Fourth Quarter and Full Year 2019 Results and Host Conference Call on February 25, 2020

2019
Amarin To Report Fourth Quarter and Full Year 2018 Results and Host Conference Call on February 27, 2019

2018
Amarin to Report Fourth Quarter and Full Year 2017 Results and Host Conference Call on February 27th, 2018

clairvoyance or time travel.

other than, "who are the members of epadi?"

i can't think of anything asked that wasn't covered in the briefing.

anyone hear something?

timeliness of filing, covered
derivative case, covered
fraud/mistake, covered
remedy, covered

Were the judges' names just announced, or something?

now 11.7M shares in the same 20 cent range, 3.41.-3.62.

ridiculous!

i see ~8.6M shares traded between 3.41-3.62.


GSCO bid 9,700 3.48, GSCO ask 9,700 3.68

any time the current bid or the current ask challenges theirs,
they scurry away from the action.

Ridiculous number of shares trading in a small range while the market is aware the stock is under accumulation.

What is with MM GSCO always at 9700 ask, always jumping away from the sale?

Mere speculation on my part, but perhaps we have a (or some) "buy everything below $n.nn" order(s) in play

Excellent to see so many 4/5 digit trades.
Real interest!

Who the hell is selling while it's now obvious sarrisa has a vacuum cleaner for amrn shares?

Could be seeing more of these daily since they now exceed 5% ownership.

fascinating, thanks!

i would sure like to review some jury instructions in relevant cases.
wouldn't even know where to look though.

no, i don't think so.
i am saying, it appears on the surface to be simple to get a jury to agree that lesser cost to a consumer is an inducement to select one product over another.

a jury trial...

dear jurists,
if you as a consumer of a product were given the option to (co)pay less for equivalent products, would you chose the greater or lesser cost product?

by show of hands, the greater cost product anyone? anyone?

Material event, yes? Where's the sec filing/PR?

Dont believe you possess adequate understanding of 3rd party payor rights to offer more than unsupported speculation. A patient can always obtain access to vascepa via self funding.

"Looking through my rose-colored investor's glasses, the ruling can be cheered by Amarin and waved in the face of every insurance company and pharmacy that tries to use formulary selection and the prior authorization process to screw Amarin out of Vascepa sales. "

could also lead to both branded and generic icosapent ethyl being entirely removed from formularies. No coverage for either branded or generic would also lead to no infringement.

When we lose hikma (the manufacturer of ALL generic vascepa rx) we lose alot of treble damages when compared to healthnet, an insurer of some covered patients with generic vascepa Rx.

(Merck, through a subsidiary, will acquire Acceleron for $180 per share)

https://www.sec.gov/Archives/edgar/data/0001331852/000110465921142280/xslF345X03/tm2133601-13_4seq1.xml

com'on joe, you can afford to do much better than 12k of AMRN
($7.4M before taxes from acceleron buyout)

https://www.sec.gov/edgar/browse/?CIK=0001331852

Has joe z. Ever purchased shares on the open market?

Not if you wish to apply the wash rule AND report being back long the stock by 12/31.

I see you, big buyer on the down low.
Too frequent 1000, 2000 share trades.

"Definitely Europe, we focused on the digital and the omnichannel launch from day one. So that’s not the change. I mean, we’ve built our model based on that and now we’re working on beyond the first 10 markets and ***what are we going to do with Central and Eastern Europe, because we believe we’re getting a lot of requests for partnerships in that area.***"

"And then, additionally, there is all the business development effort to ensure that we diversify the portfolio in a very selective way, we built a commercial infrastructure in the U.S., we’re building one in Europe. So today we can position ourselves as a true preferred partner for the next upcoming launch in the cardiometabolic space, simply because if that company partners with us, their product is going to be priority number two after VASCEPA, if it goes to a big pharma company, it’s just probably going to be a priority seven or eight, if any on their priority list."

"it"= their product

He not talking about partnering vascepa in a territory like they did in canada.

For amarin to diversify the portfolio of products, the product would have to be a new amarin partner's product.

"But we’re also investing time, effort and money into the portfolio diversification. So part of this is the lifecycle management of VASCEPA, because we believe that there are still a number of opportunities to develop indications, or more importantly, formulations, that will create value for both the patients and definitely our shareholders."

Very intriguing ...

"If Amarin stopped selling Vascepa in the US, and the generics capture 100% of the market (above and below the 500 trig level) how could there not be an infringement? How does a generic company defend them self against that?

If 10% of the market equals x, and they are selling 10x, how can they claim a blind eye to the numbers? Treble damages would certainly exceed any money "earned" from selling into the patent protected market. "

fascinating concept ... legal jeopardy due to meeting the supply demand of ALL buyers rather than just specific buyers with certain conditions.

Is there a way to track prescription rate growth in Germany?

There's a .5g capsule too.

Covid trial result is, wait for more data from other ongoing trial.

But this, this is certainty note (news) worthy

Icosapent ethyl also conferred reduced risk for sudden cardiac death (HR = 0.6; 95% CI, 0.38-0.94; P = .02) and cardiac arrest (HR = 0.44; 95% CI, 0.21-0.8; P = .02), according to the results.

If only vascepa scripts could react the same way as ivermectin's have ...


Prescriptions for ivermectin and related calls to poison control centers have shot up sharply during the latest COVID wave, and the CDC is warning healthcare professionals to steer patients away from the drug.

Scripts for the antiparasitic have risen rapidly since July, jumping to more than 88,000 in the week ending August 13, CDC researchers reported in a Health Alert Network warning. That's way up from a peak earlier this year of 39,000 for the week ending January 8, and a 24-fold increase over the pre-pandemic baseline average of 3,600 scripts per week from March 2019 to March 2020.

"Mikhail said preliminary Covid study data is scheduled for release next week at the European Society of Cardiology Congress.

“You look at what Covid patients die from, they mostly die because of an inflammatory storm,” he said. “If the study is positive, and it has value in delaying progression in Covid patients … that would be incredible.” "

spoken by a new ceo who is prepared to use better adjectives than "robust"!

let it be

https://www.intrafish.com/coronavirus/competition-for-trial-volunteers-holds-up-progress-on-promising-covid-19-treatment-made-from-fish-oil/2-1-883250

FFA EPA formulation

https://www.kdpharmagroup.com/en/news/kd-pharma-group-sla-pharma-initiate-clinical-trial-covid-19

"Healthnet,Hickma and Dr Reddy have all conspired to infringe on R-IT patents...But the case against Healthnet is the most obvious to prove."

And healthnet, if liable, has all the data necessary in their own databases to calculate the damage caused to amarin. They have everything. Rx distribution among manufacturers, Rx distribution among indications, Rx cost born by patient, insurer, manufacturer, etc ...

Theirs is a treasure trove of discovery for liability and subsequently for damages, if such is the case.

I would love the opportunity to parse healthnet's data applicable to icosapent ethyl, both branded and generic.